Caballero-Avila, M, Martín-Aguilar, L, Pascual-Goñi, E, Tejada-Illa, C, Collet, R, Rojas-García, R, Gallardo, E, Martínez-Martínez, L, Doneddu, P, Nobile-Orazio, E, de Winter, J, Alonso-Jimenez, A, del Real, MA, Armangué, T, Delmont, E, Xuclà-Ferrarons, T, Roche, JC, Jauregui, A, González, A, Ortiz, N, Liong, HF, de Rivera, FJR, Sparasci, D, Ripellino, P, Pérez-Pérez, H, Guerrero-Sola, A, Vegezzi, E, Baars, A, Jacobs, B, Wieske, L, Eftimov, F, Lleixà, C, Querol, L. CLINICAL AND IMMUNOLOGICAL RELAPSES ARE INFREQUENT IN PATIENTS WITH ANTI-CNTN1 AUTOIMMUNE NODOPATHY. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

Lewis, RA, Allen, J, Merkies, ISJ, van Doorn, PA, Sommer, C, Wallstroem, E, Luo, XD, Alonso-Alonso, M, Atassi, N, Querol, L. PHASE 3 TRIAL DESIGNS EVALUATING RILIPRUBART, A C1S-COMPLEMENT INHIBITOR, IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

Querol, L, Lewis, RA, Hartung, HP, Van Doorn, PA, Wallstroem, E, Auwarter, K, Luo, XD, Alonso-Alonso, M, Atassi, N, Hughes, RAC. PHASE 2 EFFICACY AND SAFETY OF RILIPRUBART, A C1S-COMPLEMENT INHIBITOR, IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

Van Doorn, PA, Querol, L, Hartung, HP, Hughes, RAC, Orsini, M, Hakimi-Hawken, N, Minor, C, Msihid, J, Alonso-Alonso, M, Atassi, N, Lewis, R. PHASE 2 TRIAL OF RILIPRUBART IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: QUALITY-OF-LIFE AND FATIGUE. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

Querol, L, Lewis, RA, Van Doorn, PA, Hughes, RAC, Storek, M, Rajagopal, V, Chow, T, Luo, XD, Alonso-Alonso, M, Atassi, N, Hartung, HP. PHASE 2 TRIAL OF RILIPRUBART IN CIDP: EFFECT ON COMPLEMENT BIOMARKERS AND NEUROFILAMENT LIGHT CHAIN. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

Fernandez-Eulate, G, Gitiaux, C, Thiele, S, Jungbluth, H, Audic, F, Potulska-Chromik, A, Marini-Bettolo, C, Davion, JB, de la Tassa, GM, Olivé, M, de la Hoz, CPDF, Isapof, A, Töpf, A, Walter, M, Angelini, C, Claeys, K, Kostera-Pruszczyk, A, Attarian, S, Straub, V, Domínguez-González, C, Vissing, J, Metay, C, Khraiche, D, Wahbi, K, Stojkovic, T. CLINICAL AND GENETIC SPECTRUM OF PATIENTS WITH BAG3-RELATED NEUROMUSCULAR DISORDERS IN EUROPE. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

Allen, J, Van Doorn, PA, Basta, I, Dysgaard, T, Eggers, C, Guptill, J, Gwathmey, K, Hewamadduma, C, Hofman, E, Hussain, Y, Kuwabara, S, Le Masson, G, Leypoldt, F, Lin, J, Lipowska, M, Lowe, M, Pinter, GL, Querol, L, Simu, MA, Chang, T, Tse, A, Ulrichts, P, Van Hoorick, B, Yamasaki, R, Lewis, RA. EFFICACY AND SAFETY OF SUBCUTANEOUS (SC) EFGARTIGIMOD PH20 IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: ADHERE/ADHERE plus TRIALS. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

González-Saiz, F, Vergara-Moragues, E, Trujols, J, Alcaraz, S, de los Cobos, JP. Assessing predictors of adequate individual buprenorphine maintenance dosage for the treatment of opioid use disorder: Listening to the patient. INTERNATIONAL JOURNAL OF DRUG POLICY. 2024; 130DOI:10.1016/j.drugpo.2024.104519. PMID:39024687. IF:4.400(Q1/1D).